TCGA-BH-A0EB-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 25
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- INTERFERON_ALPHA_RESPONSE+0.460
- PROTEIN_SECRETION+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- INTERFERON_GAMMA_RESPONSE+0.400
- ANGIOGENESIS+0.360
- COMPLEMENT+0.350
- IL6_JAK_STAT3_SIGNALING+0.340
- COAGULATION+0.320
- INFLAMMATORY_RESPONSE+0.320
Top 10 suppressed
- E2F_TARGETS-0.540
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V2-0.390
- MITOTIC_SPINDLE-0.240
- SPERMATOGENESIS-0.220
- MYC_TARGETS_V1-0.210
- GLYCOLYSIS-0.140
- CHOLESTEROL_HOMEOSTASIS-0.130
- WNT_BETA_CATENIN_SIGNALING-0.130
- DNA_REPAIR-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-46-3766-01A-01R-0980-07 | — | cohortSQ1 | 0.864 |
| 2 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.858 |
| 3 | TCGA-BT-A20Q-01A-11R-A14Y-07 | — | — | 0.858 |
| 4 | TCGA-05-4417-01A-22R-1858-07 | — | cohortA3 | 0.849 |
| 5 | BS_53CTGDQG | Meningioma | — | 0.843 |
| 6 | SRR8518419 | — | A | 0.832 |
| 7 | C3N-02090 | — | cohortSQ1 | 0.832 |
| 8 | 52bfcfee-5de0-4e8f-9f11-7a643858bcb0 | — | — | 0.829 |
| 9 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.827 |
| 10 | MDT-AP-2181 | Med | Medulloblastoma | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |